

# Zachary Goodman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11324878/publications.pdf>

Version: 2024-02-01

100  
papers

22,640  
citations

25014

57  
h-index

34964

98  
g-index

100  
all docs

100  
docs citations

100  
times ranked

12299  
citing authors

#	ARTICLE	IF	CITATIONS
1	Performance of Noninvasive Tests of Fibrosis Among Asians, Hispanic, and non-Hispanic Whites in the STELLAR Trials. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 90-102.e6.	2.4	9
2	BMS-986263 in patients with advanced hepatic fibrosis: 36-week results from a randomized, placebo-controlled phase 2 trial. <i>Hepatology</i> , 2022, 75, 912-923.	3.6	37
3	Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis. <i>Hepatology</i> , 2022, 75, 1235-1246.	3.6	45
4	Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study. <i>Journal of Hepatology</i> , 2022, 76, 536-548.	1.8	66
5	Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD. <i>Journal of Hepatology</i> , 2022, 76, 1030-1041.	1.8	74
6	An MMP-degraded and cross-linked fragment of type III collagen as a non-invasive biomarker of hepatic fibrosis resolution. <i>Liver International</i> , 2022, 42, 1605-1617.	1.9	9
7	From NAFLD to MAFLD: Implications of a Premature Change in Terminology. <i>Hepatology</i> , 2021, 73, 1194-1198.	3.6	266
8	Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH. <i>Hepatology</i> , 2021, 73, 625-643.	3.6	156
9	A Fibrosis-Independent Hepatic Transcriptomic Signature Identifies Drivers of Disease Progression in Primary Sclerosing Cholangitis. <i>Hepatology</i> , 2021, 73, 1105-1116.	3.6	14
10	Inter- and Intra-individual Variation, and Limited Prognostic Utility, of Serum Alkaline Phosphatase in a Trial of Patients With Primary Sclerosing Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1248-1257.	2.4	25
11	Performance of Noninvasive Liver Fibrosis Tests in Morbidly Obese Patients with Nonalcoholic Fatty Liver Disease. <i>Obesity Surgery</i> , 2021, 31, 2002-2010.	1.1	14
12	The FALCON program: Two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis. <i>Contemporary Clinical Trials</i> , 2021, 104, 106335.	0.8	38
13	Improvements of Fibrosis and Disease Activity Are Associated With Improvement of Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis. <i>Hepatology Communications</i> , 2021, 5, 1201-1211.	2.0	16
14	A Machine Learning Approach Enables Quantitative Measurement of Liver Histology and Disease Monitoring in NASH. <i>Hepatology</i> , 2021, 74, 133-147.	3.6	101
15	A Machine Learning Approach to Liver Histological Evaluation Predicts Clinically Significant Portal Hypertension in NASH Cirrhosis. <i>Hepatology</i> , 2021, 74, 3146-3160.	3.6	25
16	Comparison of ADAPT, FIB-4 and APRI as non-invasive predictors of liver fibrosis and NASH within the CENTAUR screening population. <i>Journal of Hepatology</i> , 2021, 75, 1292-1300.	1.8	27
17	Genicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design. <i>Contemporary Clinical Trials</i> , 2020, 89, 105922.	0.8	92
18	A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis. <i>Journal of Hepatology</i> , 2020, 72, 816-827.	1.8	165

#	ARTICLE	IF	CITATIONS
19	Methylation signatures in peripheral blood are associated with marked age acceleration and disease progression in patients with primary sclerosing cholangitis. <i>JHEP Reports</i> , 2020, 2, 100060.	2.6	9
20	Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension. <i>Gastroenterology</i> , 2020, 158, 1334-1345.e5.	0.6	203
21	Machine learning models identify novel histologic features predictive of clinical disease progression in patients with advanced fibrosis due to non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2020, 73, S402.	1.8	2
22	Fatigue and Pruritus in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: The Impact on Patient-Reported Outcomes. <i>Hepatology Communications</i> , 2020, 4, 1637-1650.	2.0	32
23	Association of novel markers of liver disease with neonatal liver disease in premature baboons, <i>Papio sp.</i> . <i>PLoS ONE</i> , 2020, 15, e0228985.	1.1	0
24	Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials. <i>Journal of Hepatology</i> , 2020, 73, 26-39.	1.8	290
25	Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study. <i>Hepatology</i> , 2020, 72, 892-905.	3.6	227
26	REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis. <i>Contemporary Clinical Trials</i> , 2019, 84, 105803.	0.8	105
27	Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials. <i>Hepatology</i> , 2019, 70, 1521-1530.	3.6	197
28	Reduced Patient-Reported Outcome Scores Associate With Level of Fibrosis in Patients With Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2552-2560.e10.	2.4	65
29	The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials. <i>Hepatology</i> , 2019, 70, 1913-1927.	3.6	226
30	IDDF2019-ABS-0133â€¦Routinely available noninvasive tests discriminate advanced fibrosis due to NASH in the phase 3 STELLAR trials of the ASK1 inhibitor selonsertib. , 2019, , .		0
31	Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2019, 394, 2184-2196.	6.3	818
32	Analysis of human leukocyte antigen allele polymorphism in patients with non alcoholic fatty liver disease. <i>Medicine (United States)</i> , 2019, 98, e16704.	0.4	7
33	Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease. <i>Hepatology</i> , 2019, 69, 684-698.	3.6	121
34	Assessment of liver fibrosis progression and regression by a serological collagen turnover profile. <i>American Journal of Physiology - Renal Physiology</i> , 2019, 316, G25-G31.	1.6	42
35	Improvement of hepatic fibrosis and patient-reported outcomes in non-alcoholic steatohepatitis treated with selonsertib. <i>Liver International</i> , 2018, 38, 1849-1859.	1.9	72
36	A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. <i>Hepatology</i> , 2018, 67, 1754-1767.	3.6	528

#	ARTICLE	IF	CITATIONS
37	Liver Transplantation (LT) for Cryptogenic Cirrhosis (CC) and Nonalcoholic Steatohepatitis (NASH) Cirrhosis. <i>Medicine (United States)</i> , 2018, 97, e11518.	0.4	57
38	Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , 2018, 155, 1140-1153.	0.6	253
39	Polymorphisms in the receptor for advanced glycation end-products (RAGE) gene and circulating RAGE levels as a susceptibility factor for non-alcoholic steatohepatitis (NASH). <i>PLoS ONE</i> , 2018, 13, e0199294.	1.1	15
40	The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options. <i>Journal of Hepatology</i> , 2018, 69, 1365-1370.	1.8	51
41	DNA methylation signatures reflect aging in patients with nonalcoholic steatohepatitis. <i>JCI Insight</i> , 2018, 3, .	2.3	47
42	Long-Term Follow-Up of Children Treated With Peginterferon and Ribavirin for Hepatitis C Virus Infection. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2017, 64, 89-94.	0.9	11
43	Nonalcoholic steatofibrosis independently predicts mortality in nonalcoholic fatty liver disease. <i>Hepatology Communications</i> , 2017, 1, 421-428.	2.0	101
44	Elevated prefrontal cortex GABA in patients with major depressive disorder after TMS treatment measured with proton magnetic resonance spectroscopy. <i>Journal of Psychiatry and Neuroscience</i> , 2016, 41, E37-E45.	1.4	109
45	Fibrogenesis assessed by serological type III collagen formation identifies patients with progressive liver fibrosis and responders to a potential antifibrotic therapy. <i>American Journal of Physiology - Renal Physiology</i> , 2016, 311, G1009-G1017.	1.6	69
46	Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design. <i>Contemporary Clinical Trials</i> , 2016, 47, 356-365.	0.8	178
47	The role of mitochondrial genomics in patients with non-alcoholic steatohepatitis (NASH). <i>BMC Medical Genetics</i> , 2016, 17, 63.	2.1	29
48	Long-Term Telbivudine Treatment Results in Resolution of Liver Inflammation and Fibrosis in Patients with Chronic Hepatitis B. <i>Advances in Therapy</i> , 2015, 32, 727-741.	1.3	19
49	Evaluation of Liver Fibrosis Using Texture Analysis on Combined-Contrast-Enhanced Magnetic Resonance Images at 3.0T. <i>BioMed Research International</i> , 2015, 2015, 1-12.	0.9	28
50	Current efforts and trends in the treatment of NASH. <i>Journal of Hepatology</i> , 2015, 62, S65-S75.	1.8	228
51	Anti-adipocyte antibody response in patients with non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 900-908.	1.4	4
52	Adipocytokine expression associated with miRNA regulation and diagnosis of NASH in obese patients with NAFLD. <i>Liver International</i> , 2015, 35, 1367-1372.	1.9	22
53	Expression of NALPs in adipose and the fibrotic progression of non-alcoholic fatty liver disease in obese subjects. <i>BMC Gastroenterology</i> , 2014, 14, 208.	0.8	31
54	A single non-invasive model to diagnose non-alcoholic fatty liver disease (<sc>NAFLD</sc>) and non-alcoholic steatohepatitis (<sc>NASH</sc>). <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 2006-2013.	1.4	65

#	ARTICLE	IF	CITATIONS
55	Modulation of HCV replication after combination antiretroviral therapy in HCV/HIV co-infected patients. <i>Science Translational Medicine</i> , 2014, 6, 246ra98.	5.8	19
56	Expression of energy metabolism related genes in the gastric tissue of obese individuals with non-alcoholic fatty liver disease. <i>BMC Gastroenterology</i> , 2014, 14, 72.	0.8	5
57	Predictors of All-Cause Mortality and Liver-Related Mortality in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD). <i>Digestive Diseases and Sciences</i> , 2013, 58, 3017-3023.	1.1	236
58	Efficacy and safety of boceprevir plus peginterferon+ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis. <i>Journal of Hepatology</i> , 2013, 58, 479-487.	1.8	52
59	Liver Disease After Intensive Care of Premature Baboons. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2013, 57, 172-179.	0.9	4
60	Hepatitis B-associated fibrosis and fibrosis/cirrhosis regression with nucleoside and nucleotide analogs. <i>Expert Review of Gastroenterology and Hepatology</i> , 2012, 6, 187-198.	1.4	29
61	The Association of Genetic Variants with Hepatic Steatosis in Patients with Genotype 1 Chronic Hepatitis C Infection. <i>Digestive Diseases and Sciences</i> , 2012, 57, 2213-2221.	1.1	25
62	The Combination of Ribavirin and Peginterferon Is Superior to Peginterferon and Placebo for Children and Adolescents With Chronic Hepatitis C. <i>Gastroenterology</i> , 2011, 140, 450-458.e1.	0.6	122
63	A Biomarker Panel for Non-alcoholic Steatohepatitis (NASH) and NASH-Related Fibrosis. <i>Obesity Surgery</i> , 2011, 21, 431-439.	1.1	143
64	Association of Obestatin, Ghrelin, and Inflammatory Cytokines in Obese Patients with Non-alcoholic Fatty Liver Disease. <i>Obesity Surgery</i> , 2011, 21, 1750-1757.	1.1	49
65	Pathologic criteria for nonalcoholic steatohepatitis: Interprotocol agreement and ability to predict liver-related mortality. <i>Hepatology</i> , 2011, 53, 1874-1882.	3.6	525
66	Reply:. <i>Hepatology</i> , 2011, 54, 370-371.	3.6	1
67	Non-alcoholic steatohepatitis (NASH) in patients with polycystic ovarian syndrome (PCOS). <i>Scandinavian Journal of Gastroenterology</i> , 2011, 46, 479-484.	0.6	63
68	Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. <i>Hepatology</i> , 2010, 52, 886-893.	3.6	840
69	Farglitazar Lacks Antifibrotic Activity in Patients With Chronic Hepatitis C Infection. <i>Gastroenterology</i> , 2010, 138, 1365-1373.e2.	0.6	86
70	Phosphoproteomic Biomarkers Predicting Histologic Nonalcoholic Steatohepatitis and Fibrosis. <i>Journal of Proteome Research</i> , 2010, 9, 3218-3224.	1.8	21
71	Independent Predictors of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 1224-1229.e2.	2.4	270
72	A Novel Diagnostic Biomarker Panel for Obesity-related Nonalcoholic Steatohepatitis (NASH). <i>Obesity Surgery</i> , 2008, 18, 1430-1437.	1.1	255

#	ARTICLE	IF	CITATIONS
73	Efficacy and Safety of Entecavir in Patients With Chronic Hepatitis B and Advanced Hepatic Fibrosis or Cirrhosis. <i>American Journal of Gastroenterology</i> , 2008, 103, 2776-2783.	0.2	114
74	Telbivudine versus Lamivudine in Patients with Chronic Hepatitis B. <i>New England Journal of Medicine</i> , 2007, 357, 2576-2588.	13.9	735
75	A systems biology approach to the pathogenesis of obesity-related nonalcoholic fatty liver disease using reverse phase protein microarrays for multiplexed cell signaling analysis. <i>Hepatology</i> , 2007, 46, 166-172.	3.6	48
76	Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 Years. <i>Gastroenterology</i> , 2006, 131, 1743-1751.	0.6	832
77	Gene Expression of Leptin, Resistin, and Adiponectin in the White Adipose Tissue of Obese Patients with Non-Alcoholic Fatty Liver Disease and Insulin Resistance. <i>Obesity Surgery</i> , 2006, 16, 1118-1125.	1.1	98
78	Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis B. <i>New England Journal of Medicine</i> , 2006, 354, 1011-1020.	13.9	1,118
79	A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis B. <i>New England Journal of Medicine</i> , 2006, 354, 1001-1010.	13.9	1,345
80	Predictors of Nonalcoholic Steatohepatitis and Advanced Fibrosis in Morbidly Obese Patients. <i>Obesity Surgery</i> , 2005, 15, 310-315.	1.1	276
81	Hepatic gene expression in patients with obesity-related non-alcoholic steatohepatitis. <i>Liver International</i> , 2005, 25, 760-771.	1.9	100
82	A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease. <i>Hepatology</i> , 2005, 42, 665-674.	3.6	209
83	Long-Term Therapy with Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B. <i>New England Journal of Medicine</i> , 2005, 352, 2673-2681.	13.9	524
84	Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. <i>Gastroenterology</i> , 2004, 126, 1750-1758.	0.6	804
85	Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. <i>Hepatology</i> , 2003, 38, 75-85.	3.6	531
86	Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen-Positive Chronic Hepatitis B. <i>New England Journal of Medicine</i> , 2003, 348, 808-816.	13.9	1,297
87	Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders. <i>Journal of Hepatology</i> , 2003, 38, 818-826.	1.8	130
88	Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen-Negative Chronic Hepatitis B. <i>New England Journal of Medicine</i> , 2003, 348, 800-807.	13.9	971
89	Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. <i>Gastroenterology</i> , 2002, 122, 1303-1313.	0.6	1,059
90	Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2001, 34, 730-739.	1.8	666

#	ARTICLE	IF	CITATIONS
91	Is an $\alpha$ 1/2 la carte? combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C?. Hepatology, 2000, 31, 211-218.	3.6	359
92	Impact of Interferon Alfa-2b and Ribavirin on Progression of Liver Fibrosis in Patients With Chronic Hepatitis C. Hepatology, 2000, 32, 1131-1137.	3.6	257
93	Lamivudine as Initial Treatment for Chronic Hepatitis B in the United States. New England Journal of Medicine, 1999, 341, 1256-1263.	13.9	1,269
94	Pruritus as a presenting symptom of chronic hepatitis C. Digestive Diseases and Sciences, 1998, 43, 2177-2183.	1.1	63
95	Histopathology of Hepatitis C Virus Infection. Seminars in Liver Disease, 1995, 15, 70-81.	1.8	248
96	A 39 Year Old Man with Chronic Hepatitis. Seminars in Liver Disease, 1994, 14, 97-105.	1.8	50
97	A 51-Year-Old Woman with Elevated Liver Enzymes Seven Months After Transplantation for Primary Biliary Cirrhosis. Seminars in Liver Disease, 1992, 12, 93-100.	1.8	3
98	A 22-Year-Old Man with Thyroid Cancer and Cholestatic Liver Disease. Seminars in Liver Disease, 1991, 11, 64-71.	1.8	9
99	Small Bile Duct Abnormalities in Sarcoidosis. Journal of Clinical Gastroenterology, 1990, 12, 555-561.	1.1	62
100	Recombinant Interferon Alfa Therapy for Chronic Hepatitis C. New England Journal of Medicine, 1989, 321, 1506-1510.	13.9	1,278